Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron,

Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts -
       Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 25, 2013

NEW YORK, November 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Hologic, Inc. (NASDAQ: HOLX), Regeneron
Pharmaceuticals Inc. (NASDAQ: REGN), OPKO Health Inc. (NYSE: OPK), and Unilife
Corp. (NASDAQ: UNIS). Today's readers may access these reports free of charge
- including full price targets, industry analysis and analyst ratings - via
the links below.

Gilead Sciences, Inc. Research Report

On November 18, 2013, Gilead Sciences, Inc. (Gilead) announced that its Phase
3 study (Study 116) evaluating idelalisib in combination with rituximab in
previously-treated chronic lymphocytic leukemia (CLL) in patients who were not
fit for chemotherapy was accepted for presentation during a late-breaking
abstracts session at the Annual Meeting of American Society of Hematology
(ASH) in New Orleans (Abstract #LBA-6). Gilead reported that Study 116 was
stopped early based on a pre-specified interim analysis performed by an
external Data Monitoring Committee (DMC) showing a highly statistically
significant effect on the primary endpoint of progression-free survival.
Gilead added that during the study, safety was in line with previous
observations, and was consistent with advanced disease patients receiving CD20
antibody therapy. The Company informed that it will present detailed results
from the study at ASH on December 10, 2013. The Full Research Report on Gilead
Sciences, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9898_GILD

--

Hologic, Inc. Research Report

On November 14, 2013, Hologic, Inc. (Hologic) announced that holders of the
2.00% Convertible Senior Notes due 2037 (CUSIP No. 436440 AA9) issued December
10, 2007 (the Notes) have the right to surrender their Notes for repurchase by
the Company pursuant to their option (the Put Option) under the Indenture
governing the Notes, dated as of December 10, 2007 (the Base Indenture) as
supplemented by the First Supplemental Indenture, dated as of December 10,
2007 (the Supplemental Indenture and together with the Base Indenture, the
Indenture). The Company added that with the Put Option, each holder of the
Notes can require the Company to repurchase all or any part (in principal
amount equal to $1,000 or integral multiples thereof) of such holder's Notes
on December 13, 2013 (the Put Option Repurchase Date) at a repurchase price
(the Put Option Repurchase Price) equal to 100% of the principal amount of the
Notes, plus accrued and unpaid interest to, but not including, the Put Option
Repurchase Date, upon the terms and subject to the conditions set forth in the
Indenture and the Notes. Hologic further informed that the holders of Notes
may exercise Put Option starting 9:00 a.m. New York City Time on the date of
the announcement until 5:00 p.m. New York City Time on December 12, 2013. The
Full Research Report on Hologic, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/d132_HOLX

--

Regeneron Pharmaceuticals Inc. Research Report

On November 20, 2013, Regeneron Pharmaceuticals Inc.'s stock rose 0.33%,
ending the day at $274.68. Over the previous three trading sessions, shares of
Regeneron declined 1.90% compared to the Nasdaq Composite which declined 1.62%
during the same period. The Full Research Report on Regeneron Pharmaceuticals
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8ea7_REGN

--

OPKO Health Inc. Research Report

On November 15, 2013, OPKO Health Inc. (OPKO) has completed patient
recruitment in the first phase 3 trial of Rayaldy to treat patients with
secondary hyperparathyroidism (SHPT), stage 3 or 4 kidney (CKD) and vitamin D
insufficiency. According to the Company, this trial is the first of two
identical randomized, double-blind, placebo-controlled, multi-site studies
intended to establish the safety and efficacy of Rayaldy as a new treatment
for SHPT in the targeted population. OPKO added that the endpoints of both
studies (being conducted in parallel), include vitamin D status and changes in
serum calcium, serum phosphorus, and plasma intact parathyroid hormone. OPKO
informed that top-line data from both trials are expected in mid-2014. The
Full Research Report on OPKO Health Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/cd43_OPK

--

Unilife Corp. Research Report

On November 20, 2013, Unilife Corp. (Unilife) announced that it has signed a
long-term commercial supply contract with Hikma Pharmaceuticals PLC (Hikma)
for the use of Unifill prefilled syringes with a range of generic injectable
drugs. Unilife reported that it will supply Hikma with customized prefillable
delivery systems from its Unifill platform, including the Unifill syringe and
the Unifill Nexus under the 15-year global agreement. Unilife informed that it
will begin product sales to Hikma in early 2014. Under the terms of the
contract, Unilife stated that it will supply Hikma a minimum volume of 175MM
units per year following a rapid high-volume ramp up period. In addition,
Unilife confirmed that Hikma will pay Unilife $40 million in upfront and
milestone payments, beginning with an initial upfront payment of $5 million
immediately, and followed by an addition $15 million in payments expected
during 2014. However, Unilife added that the final $20 million in
milestone-based payments will be paid the following year. The Full Research
Report on Unilife Corp. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cb4d_MSFT

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.